OmniaBio is redefining the future of cell therapy manufacturing through its proprietary AI-powered Intelligent Factory™. Purpose-built to accelerate discoveries and industrialize production, the Intelligent Factory™ integrates artificial intelligence and automation across the entire manufacturing lifecycle.
With a focus on autologous CAR-T and other advanced therapies, OmniaBio’s platform enables scalable, efficient, and high-fidelity production by embedding predictive analytics, robotic bioprocessing, and digital quality systems into a unified, closed-loop system. This approach not only enhances throughput and consistency but also positions OmniaBio as a next-generation CDMO partner for innovators seeking to bring life-saving therapies to patients faster.
Company Details
- Employees
- 162
- Founded
- 2022
- Address
- 190 Longwood Rd S, Hamilton,ontario L8p 0a6,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.omniabio.com
- Keywords
- in M&A.
- HQ
- Hamilton, Ontario
Omniabio Questions
Omniabio's website is http://www.omniabio.com
Omniabio's LinkedIn profile is https://ca.linkedin.com/company/omniabiocdmo
Omniabio has
162 employees.
View email and phone details for 162
employees at Omniabio.
Omniabio's industry is
Biotechnology Research
Omniabio's top competitors are
Biovectra,
Fusion Pharmaceuticals,
Sanofi,
Notch Therapeutics,
Bluerock Therapeutics,
Ccrm,
Atomvie Global Radiopharma Inc.,
Biotalent Canada,
Stemcell Technologies,
Virica Biotech.
Omniabio's categories are Biotechnology Research
Omniabio's founding year is 2022
